Preterm birth · women with a twin pregnancy
Oral betamimetic showed no clear difference in preterm birth (less than 37 weeks' gestation) compared with placebo (low certainty).
1 finding from 1 review
Preterm birth less than 34 weeks' gestation · women with a twin pregnancy
Oral betamimetic showed no clear difference in very preterm birth (less than 34 weeks' gestation) compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
All cause mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of severe infections (Grade III or IV) · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in incidence of severe infections (Grade III or IV) (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in adverse events Toxic deaths (low certainty).
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
It is very uncertain whether the intervention changes incidence of febrile neutropenia (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of severe infections · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All cause mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with acute myocardial infarction
Lidocaine showed no clear difference in all‐cause mortality compared with placebo or no intervention (low certainty).
1 finding from 1 review
Overall survival at 30 days after myocardial infarction · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ventricular fibrillation · patients with myocardial infarction
It is very uncertain whether lidocaine changes ventricular fibrillation compared with disopyramide (very low certainty).
1 finding from 1 review
Adverse events (AEs; adverse drug reaction): asystole · patients with myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): asystole compared with disopyramide (very low certainty).
1 finding from 1 review
Adverse events (AEs; adverse drug reaction): sinoatrial block · patients with myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): sinoatrial block compared with disopyramide (very low certainty).
1 finding from 1 review
Adverse events (AEs; adverse drug reaction): cardiac blocks (high‐degree atrioventricular block and bundle) · patients with myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): cardiac blocks… compared with disopyramide (very low certainty).
1 finding from 1 review